Amgen reaches deal to buy Horizon Therapeutics for $28 billion
Amgen Inc.
said Monday it has agreed to acquire Horizon Therapeutics Plc HZNP, +0.39% in an all-cash deal valued at $27.8 billion, confirming earlier reports and a deal that was first mooted in November. Under the terms of the deal, Amgen will pay $116,50 per each Horizon share owned, equal to a 47.9% premium over the stock's closing price on Nov. 29, the day before the deal was first announced. It's equal to a premium of 19.7% over the stock's closing price Friday at $97.29.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
WSJ News Exclusive | Amgen in Advanced Talks to Buy Horizon TherapeuticsAmgen is in advanced talks to buy drugmaker Horizon Therapeutics, people familiar with the matter say, in a deal likely to be valued at well over $20 billion
Read more »
Amgen reportedly in talks to buy Horizon TherapeuticsThe U.S. biotechnology company AMGN was the last of three suitors standing in an auction for Horizon, according to sources cited by The Wall Street Journal.
Read more »
Amgen set to buy biotech firm Horizon at $26 bln valuation - Bloomberg NewsAmgen Inc is set to buy biotech firm Horizon Therapeutics Plc at a valuation of about $26 billion in what would be its largest acquisition, Bloomberg News reported on Monday.
Read more »
Amgen emerges frontrunner in Horizon deal as Sanofi drops bidAmgen Inc is in advanced talks to buy biotech company Horizon Therapeutics Plc , the Wall Street Journal reported on Sunday, while rival bidder French health group Sanofi announced it had dropped its bid.
Read more »
CEO of crypto news site The Block resigns for failing to disclose $27M loans from Alameda ResearchCEO Mike McCaffrey reportedly made an executive decision to restructure The Block in 2021, which involved a series of loans totaling $27 million from Alameda Research.
Read more »
Sanofi says it does not intend to make an offer for HorizonFrench health group Sanofi said on Sunday that it no longer intends to make an offer for Horizon Therapeutics Plc.
Read more »